The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study

There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR...

Descripción completa

Detalles Bibliográficos
Autores: van Weelden, Willem Jan, Mancebo Moreno, Gemma, Amant, Frédéric, ENITEC-Consortium
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/48174
Acceso en línea:http://hdl.handle.net/10230/48174
http://dx.doi.org/10.1016/j.humpath.2020.12.003
Access Level:acceso abierto
Palabra clave:Cutoff
Endometrial cancer
Estrogen receptor
Progesterone receptor
Prognostic biomarker
id ES_a4841dee1f190553bdf2ca5a583dbd57
oai_identifier_str oai:repositori.upf.edu:10230/48174
network_acronym_str ES
network_name_str España
repository_id_str
spelling The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration studyvan Weelden, Willem JanMancebo Moreno, GemmaAmant, FrédéricENITEC-ConsortiumCutoffEndometrial cancerEstrogen receptorProgesterone receptorPrognostic biomarkerThere is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1-2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1-30%. Sensitivity was highest for the cutoff values of 80-90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0-10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9-83.3%); 20-80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0-93.9%); and 90-100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8-100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0-10%), intermediate-risk (20-80%), and low-risk (90-100%) group.Elsevier202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/48174http://dx.doi.org/10.1016/j.humpath.2020.12.003reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraEspañol© Elsevier http://dx.doi.org/10.1016/j.humpath.2020.12.003info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/481742026-06-12T07:21:37Z
dc.title.none.fl_str_mv The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
title The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
spellingShingle The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
van Weelden, Willem Jan
Cutoff
Endometrial cancer
Estrogen receptor
Progesterone receptor
Prognostic biomarker
title_short The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
title_full The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
title_fullStr The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
title_full_unstemmed The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
title_sort The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a european network for individualized treatment of endometrial cancer collaboration study
dc.creator.none.fl_str_mv van Weelden, Willem Jan
Mancebo Moreno, Gemma
Amant, Frédéric
ENITEC-Consortium
author van Weelden, Willem Jan
author_facet van Weelden, Willem Jan
Mancebo Moreno, Gemma
Amant, Frédéric
ENITEC-Consortium
author_role author
author2 Mancebo Moreno, Gemma
Amant, Frédéric
ENITEC-Consortium
author2_role author
author
author
dc.subject.none.fl_str_mv Cutoff
Endometrial cancer
Estrogen receptor
Progesterone receptor
Prognostic biomarker
topic Cutoff
Endometrial cancer
Estrogen receptor
Progesterone receptor
Prognostic biomarker
description There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1-2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1-30%. Sensitivity was highest for the cutoff values of 80-90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0-10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9-83.3%); 20-80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0-93.9%); and 90-100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8-100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0-10%), intermediate-risk (20-80%), and low-risk (90-100%) group.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/48174
http://dx.doi.org/10.1016/j.humpath.2020.12.003
url http://hdl.handle.net/10230/48174
http://dx.doi.org/10.1016/j.humpath.2020.12.003
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv © Elsevier http://dx.doi.org/10.1016/j.humpath.2020.12.003
info:eu-repo/semantics/openAccess
rights_invalid_str_mv © Elsevier http://dx.doi.org/10.1016/j.humpath.2020.12.003
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415503171158016
score 15,81155

Similares en LA Referencia